Alkem Laboratories Ltd — Q3 FY26
Alkem delivered a stable Q3 with total revenue of ₹3,737 crore (+10.7% YoY) and EBITDA margin of 22.2%.
bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
88%Questions answered0Evaded / deflected12Questions auditedMixedNumbers vs filing
Answered
High priority
Scale and investment required for medtech over 3-5 years.
Asked by Damayanti Kerai, HSBC
Management gave specific revenue target and margin range.
Read the exchange
Question
what kind of scale you want to build over next 3 to 5 years and then what kind of investment or cost will be required to build that scale
Sundiv (management)
in the next 3 to 5 years revenue could be around 1,000 crores and a bit would be around say 20 22% 25% would take higher
Partial answer
Medium priority
Confidence in scaling medtech and major challenges.
Asked by Damayanti Kerai, HSBC
Answered confidence but did not discuss challenges.
challenges not addressed
Read the exchange
Question
what gives you so much of confidence that you can really scale up big in just a matter of say 3 to 5 years. what could be the major challenges
Costa (management)
we are in the process of building the team and with the ortho we have already built the team and the people we have brought in are from large global companies with significant experiences
Answered
High priority
Details on acquisition: history, product segment, geography, financials.
Asked by Taher Mukharji, Namura
Provided detailed strategic rationale and financial projections.
Read the exchange
Question
if you can provide some more color on this acquisition ... product segment geography any concentration risk ... strategic rational ... financial metric ... ebitda margin ... break even timeline
Sundiv (management)
this is a research-oriented company which has solved one of the biggest medtech problem ... third largest company in the world ... revenue coming from western Europe and US to the tune of 85% ... already EBITDA positive ... 10% EBITDA by FY27 ... 23 to 24% in 3 years
Answered
Medium priority
Why 55% stake and plan to own 100%?
Asked by Taher Mukharji, Namura
Explained rationale and potential future acquisition.
Read the exchange
Question
why not owning 100%? Is there a plan to own 100% at some point in time?
Sundiv (management)
the balance shareholders they want to retain their shareholding ... maybe after 3 4 years we can again look at buying the balance stake from them.
Answered
High priority
Incremental investment for growing the acquired assets.
Asked by Nha M, BHA
Provided specific investment numbers.
Read the exchange
Question
what is the incremental investment that we are planning on growing the optitude assets.
Sundiv (management)
initial investment will be of around 1100 crores ... we will maybe invest 100 to 200 crores more over next two years to fund their R&D program.
Partial answer
Medium priority
Payback period for the acquisition.
Asked by Nha M, BHA
Gave base payback but vague on improved scenario.
no specific number for improved payback
Read the exchange
Question
what would be the payback period for the acquisition based on your initial assessment?
Sundiv (management)
the payback is around 10% uh 10 years on this asset but after considering LA ... the payback will significantly be lower
Answered
High priority
Why domestic formulation growth is below IPM.
Asked by Kunal Dhamesha, McQueen
Provided YTD growth numbers and explained base effect.
Read the exchange
Question
what is happening in our domestic formulation business that continues to grow at a lower level much lower than the IPM level
Dr. Vikas (management)
if you look at our YTD numbers, we are close to 10% ... if you remove that, we are actually close to around 11% or 12% ... in a market which is growing at around 7 and 1/2 to 8%
Answered
High priority
Gross margin profile of acquired business and margin improvement drivers.
Asked by Kunal Dhamesha, McQueen
Provided current gross margin and detailed drivers.
Read the exchange
Question
how is the gross margin profile of the business and when we say we'll improve the EBITDA margin from around 4% to more like 25% over the next 3 to 5 years is it more driven by operating leverage gross margin improvement
Costa (management)
the gross margin of the company is as of now close to 73% ... operating leverage ... optimize cost ... new products in high ASP market ... PFO in US ASPs almost $9,500
Answered
Medium priority
Plan to refinance the 450-500 cr debt at high interest.
Asked by Kunal Dhamesha, McQueen
Clearly stated refinancing plan and expected rate reduction.
Read the exchange
Question
the 450 500 cr debt on the balance sheet which is at a high interest rate. So is there a plan to provide loan from the Alchem balance sheet or refinance?
Sundiv (management)
we will not provide loan from Alchem India but definitely we will get it refinanced with help of corporate guarantee. The rate can be reduced from current 10% to 5 to 6% easily.
Answered
Medium priority
Reason for divergence between primary and secondary sales in India.
Asked by Nik Matu, HTSC Mutual Fund
Explained the base effect and confirmed correction.
Read the exchange
Question
any particular reason for this divergence between the two and when do you see this anomaly getting corrected?
Dr. Vikas (management)
There is no divergence or no anomaly in this number. It is just a cut off adjustment ... spillover impact which already got corrected in Q3.
Partial answer
High priority
Gross margin guidance for FY27-28 in light of MIP on PNG.
Asked by Nik Matu, HTSC Mutual Fund
Gave impact size but margin guidance was tentative.
impact range vagueno firm guidance
Read the exchange
Question
any particular guidance on the gross margin going into FY27 FY28 especially in light of the MIP that has been announced for PNG and its derivatives?
Dr. Vikas (management)
close to say a 8200 crores impact ... we will try and see how we minimize that impact ... similar guidance on the gross margin maybe a .5 to a percentage basis points here there
Answered
High priority
Growth breakdown for acquisition: new products vs new markets.
Asked by Chirat Bagley, DSP Mutual Fund
Clearly outlined three growth drivers.
Read the exchange
Question
this incremental growth ... is going to come new products in similar markets or similar products in newer markets?
Costa (management)
three things: newer products like PFO in US, increasing footprint in emerging markets, going deep into markets where we have low market share.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| Medtech revenue target of 1,000 crores in 3-5 years | ₹1,000 cr | ₹3,737 cr | Understated vs filing |
| Medtech EBITDA margin target 20-25% in 3-5 years | 22% | 22% | Matches filing |
| EBITDA margin target of 10% by FY27 for acquired company | 10% | 22% | Understated vs filing |
| EBITDA margin target of 23-24% in 3 years for acquired company | 24% | 22% | Overstated vs filing |
| Revenue estimate of 600 crores for calendar year 2026 | ₹600 cr | ₹3,737 cr | Understated vs filing |
| Revenue target of 780 crores for acquired company | ₹780 cr | ₹3,737 cr | Understated vs filing |
| 14% CAGR growth for acquired company over 5 years | 14% | 10.7% | Overstated vs filing |
| Gross margin impact of 0.5 to 1 percentage point from MIP | 100 bps | -35 bps | Overstated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.